Why Your Insurer Is Paying a Premium for Weight Loss Drugs

There is a new math problem for American health insurers, and the answer is not what anyone in the room wants to see. In a study published this week in Health Affairs, researchers found that spending at Blue Cross Blue Shield of Massachusetts jumped by 11.8% in fiscal 2025. That is a massive acceleration from the 6.8% growth seen just the year before. The primary driver is not a rise in cancer treatments or hospital stays. It is the skyrocketing cost of GLP-1 drugs, the class of medications now central to both weight loss and diabetes management.

The Massachusetts Anomaly

Why is this insurer in the crosshairs? Blue Cross Blue Shield covers roughly 1.8 million to 2 million residents in the state. It is a microcosm of the national affordability crisis. The study, co-authored by experts from Harvard University and the insurer itself, analyzed claims data from 2018 through the first half of 2025. They found that spending growth in Massachusetts has outpaced the rest of the country by several percentage points. The reason is specific: Massachusetts insurers have historically been more generous with GLP-1 coverage than their peers elsewhere.

This generosity has now become a liability. As more patients demand these treatments, the cost burden shifts heavily onto the insurer. The data shows a clear trend line. Spending growth was 1.2% in 2019, climbed to 6.8% in fiscal 2024, and then spiked to nearly 12% in fiscal 2025. This is not a static problem. It is an accelerating one that is forcing a reevaluation of how these drugs are paid for.

The Cost of Access

The immediate consequence of this spending surge is a squeeze on other areas of care. The study highlights that soaring premiums and out-of-pocket costs are forcing residents to delay seeking care. Some are even sacrificing the ability to pay for groceries. This is the trade-off. To keep GLP-1s accessible, insurers are absorbing costs that ripple out to every other policyholder. The result is a higher baseline premium for everyone, whether they use the drug or not.

Governor Maura Healey’s Health Care Affordability Work Group has begun to push back. Their recommendations include leveraging state purchasing power to lower drug costs. They also propose establishing default out-of-network payment rates. These are attempts to break the pricing power that pharmaceutical companies hold over insurers. However, the scale of the GLP-1 expense makes these levers feel small against the financial pressure.

A National Pattern

Massachusetts is not an isolated case. Across the country, insurers are grappling with the same issue. Commercial insurers, MassHealth, and the Group Insurance Commission have all stopped covering GLP-1 drugs for weight loss due to massive cost pressures. This is a direct response to the unsustainable trajectory of spending. The decision to cut coverage is not about denying care. It is about financial survival for the insurance model itself.

Critics argue that this move exacerbates health disparities. If only the wealthy can afford these drugs out of pocket, the health benefits of GLP-1s remain out of reach for most. The insurers are caught in a bind. They must manage costs to remain solvent, but doing so limits access to a treatment that has shown significant health benefits. The tension between affordability and access is now the central debate in American healthcare.

The Road Ahead

The future of GLP-1s in insurance plans is uncertain. The study suggests that the current model of generous coverage is not sustainable without significant changes to drug pricing or payment structures. Insurers will likely continue to tighten their policies. Patients may face higher deductibles or stricter prior authorization requirements. The goal for policymakers is to find a middle ground where these drugs remain accessible without bankrupting the insurance system.

For now, the data is clear. GLP-1s are the single largest driver of spending growth in the Massachusetts market. As the drugs become more common, the financial impact will only grow. The industry is being forced to adapt. The question is whether the adaptations will preserve access or close the door on a treatment that has changed the landscape of chronic disease management.